MAC.L $1.52 -10.8824%
IFCM3.SA $1.08 0%
PFBC $44.44 -1.3322%
SESG.PA $5.93 1.89%
BAZA3.SA $68.64 2.5856%
0144.HK $12.18 -1.9324%
CBL $22.03 -2.479%
NVDA $281.44 -1.5204%
RKW.L $2 020.00 0%
RENT $2.27 -4.8319%
BHSE $11.95 661.146%
SXQG $22.62 0.5038%
0331.HK $6.05 -1.3051%
OXLC $5.19 -0.3647%
KAT.L $0.11 5%
SRVR $28.98 -0.6173%
XPXD.L $68.81 -0.4485%
IPB $25.33 0%
SWKH $17.19 -0.1162%
CYAN $0.99 4.1996%
USBF $86.22 1.26857%
CFVIW $3.86 0%
RMT $8.03 -0.4957%
PEB-PE $19.01 0.0526%
ZWS $20.86 -0.263%
BS6.SI $1.18 -3.2787%
WHI.L $20.50 7.8947%
AMTX $1.71 -3.3898%
FORT.L $189.20 -0.7345%
PGRWW $0.00 0%
TRTN $82.55 -0.1451%
KAIIW $0.04 0%
1916.HK $0.99 -1%
SUPN $33.39 -6.9916%
GMAT3.SA $6.59 -1.9345%
0P0001K1DQ.L $12 133.40 0.364%
0196.HK $0.20 3.5533%
BSAC $19.75 0.5089%
TMF $8.38 -1.2485%
0DP4.L $39.85 0%
0IUV.L $182.00 1.5625%
GXTG $24.93 0.1205%
AON $334.33 -0.2655%
GLDW $152.82 0%
CTRG.PA $9.44 0%
HY $49.99 -0.6755%
0QZF.L $32.85 1.1082%
FCUV $1.86 -6.5327%
0RCW.L $89.90 -0.882%
BPTH $1.47 -3.2385%
1762.HK $0.19 0.5405%
DIBS $3.88 -3.2419%
MOXC $0.90 -3.7766%
RFEU $61.84 -0.242%
IBTL $21.26 -0.4467%
BN4.SI $6.40 -0.4666%
AKR $13.13 -0.1901%
FAS $54.28 -2.6368%
ISLE $10.01 0%
PSCM $64.52 -0.1611%
KW $14.47 -2.6263%
0DSJ.L $10.86 -4.0636%
LIB.L $8.50 -10.5263%
POWWP $24.50 0.7608%
CRIS $0.93 2.4286%
AL $37.74 -1.1396%
UNG.L $11.50 0%
LEDD $39.24 0%
AAC.PA $9.85 0%
JIBG.L $63.37 -1.68334%
6158.HK $0.16 -2.3809%
TYL $388.60 -0.0051%
ALL-PG $24.99 0%
AMNA $37.48 0%
FLFVU $10.54 0%
DBDRU $0.00 0%
MLSDN.PA $30.00 0%
0P000147Q3.L $11 639.30 -0.4456%
ZHDG $16.32 -0.8807%
HCDIP $5.45 4.2065%
BODY $0.45 -0.4651%
JPEL.L $1.08 0%
DUETU $10.38 0%
TWCTU $9.61 0%
0F2S.L $46.10 1.9911%
AJBU.SI $2.17 0%
ESP.L $90.10 -0.6615%
BNGOW $0.06 1.3986%
RYJ $53.09 -0.847%
BSA $25.26 0%
JT $1.16 -5.6911%
AHI $0.32 -8.8813%
PLXS $85.88 0.0699%
SSBI $15.04 -3.0851%
PDTC3.SA $2.47 -8.1784%
0KFU.L $13.35 2.6933%
DHCAW $0.03 -38.8%
FNG $10.41 0%
BSX $52.98 -0.7773%
VIEW $0.23 -4.3387%
Eng
Логотип
Eng
Лого

ReNeuron Group plc RENE.L

$7.75

На 18:02, 12 мая 2023

Ранг: 3

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    4631078.00000000

  • week52high

    39.00

  • week52low

    7.95

  • Revenue

    403000

  • P/E TTM

    -48

  • Beta

    1.01641200

  • EPS

    -0.13000000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    03 июл 2023 г. в 07:30

Описание компании

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек